Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks ...

The most recent trading session ended with Medtronic (MDT) standing at $79.30, reflecting a -0.23% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 1.08%. On the other hand, the Dow registered a gain of 0.32%, and the technology-centric Nasdaq increased by 1.58%.The the stock of medical device company has fallen by 2.65% in the past month, lagging the Medical sector's gain of 0.31% and the S&P 500's gain of 0.43%.Market participants will be closely following the ...

MicroStockHub/iStock via Getty Images Everybody knows buying stocks entails risk, whether it be failure of the business model or from paying too much for a stock. While those are legitimate concerns, a lesser talked form of risk is the risk of not buying stocks, or not putting capital to work in a meaningful way outside of a high yield savings account and Treasury Bonds. While savings accounts still yield a meaningful amount compared to 2 years ago, those yields may decline over the next 12 months and b ...

Medtronic (MDT) closed the most recent trading day at $78.10, moving +1.32% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.64%. On the other hand, the Dow registered a gain of 1.85%, and the technology-centric Nasdaq increased by 0.2%. The the stock of medical device company has fallen by 3.59% in the past month, lagging the Medical sector's gain of 0.71% and the S&P 500's gain of 3.82%. Market participants will be closely following the financial result ...

The short answer: More than many of its peers, at least in terms of yield.Medtronic (MDT -1.12%), a beast of a medical-device company, has caught the eye of more than a few income investors. It has enacted dividend raises at least once annually for a hard-to-beat 47 years straight and approaches high-yield dividend territory with a payout hovering just below 4%. As that distribution is a major part of the stock's popularity, it's worth looking at a key number behind it -- quite simply, how much will it amou ...

shapecharge/E+ via Getty Images Introduction Medtronic (NYSE:MDT) has been an underperformer over the last few years. However, with the recent pullback while earnings have continued to climb higher, I think shares of Medtronic are cheap at the current price. My bullish investment thesis is driven by my optimistic outlook on the EPS growth long-term, which is sustained by growth in medtech markets and a huge pipeline of products. I rate shares as a 'buy' with a view towards shareholder friendly capital alloc ...

Core Insights - The integration of artificial intelligence (AI) in healthcare is poised to enhance patient outcomes through improved diagnostics and data processing capabilities, potentially creating a new segment in the stock market that merges technology and biotechnology [1] Group 1: AI Healthcare Stocks Overview - AI healthcare stocks are still largely speculative but should be evaluated based on the number of patients and conditions they can address using AI technology [1] - The vast amounts of health data collected for training AI systems are highly valuable, contributing to the worth of AI healthcare stocks [1] Group 2: Recursion Pharmaceuticals (RXRX) - Recursion Pharmaceuticals aims to transform clinical-stage biotechnology through algorithmic applications, focusing on reducing the time and cost of drug production [2] - The company is in early stages and lacks a proven track record of marketable drugs, but its proprietary software platform automates lab experiments and data collection, compiling a significant biological and chemical dataset [2][3] - RXRX's application of supercomputing technology and custom-trained AI could revolutionize drug research and production, making it a noteworthy AI healthcare stock despite its recent challenges [3] Group 3: Novartis (NVS) - Novartis has integrated AI into its processes, utilizing it for Generative Chemistry, AE Brain, and AI Nurse applications to enhance drug development and patient engagement [4][5] - The company employs top chemists and has successfully brought over 90 products to market, indicating a strong position in the pharmaceutical industry [5] - Novartis's broad approach to AI in healthcare makes it a compelling investment opportunity [5] Group 4: Medtronic (MDT) - Medtronic is recognized for its innovative AI healthcare technologies, particularly the GI Genius, an AI-based endoscopy module that improves the detection of colorectal polyps [6] - The company's focus on technology development for healthcare applications positions it favorably as the industry increasingly adopts AI solutions [6][7] - Medtronic's advancements in AI are seen as a positive indicator for potential investment as the healthcare sector evolves [7]

Core Viewpoint - Medtronic is facing challenges in the Medical Products industry due to geopolitical pressures, supply chain issues, and disappointing fiscal guidance, leading to underperformance compared to peers [1][3][11] Company Performance - Medtronic's stock closed at $77.12, reflecting a decline of over 2% from the previous day, and has lost 5.2% over the past month, underperforming the industry's 0.8% decline and the S&P 500's 3.5% growth [1][2] - The company reported strong fiscal fourth-quarter 2024 results but provided cautious fiscal 2025 guidance that fell short of market expectations, disappointing investors [3][11] Industry Context - The Medical Products industry has been affected by rising freight costs and shipping lead times due to geopolitical tensions, particularly around the Red Sea [1] - The global inflation rate is projected to decline from 6.8% in 2023 to 5.9% in 2024, which has improved investor sentiment for some MedTech companies, but Medtronic has not benefited similarly [1] Trade Relations Impact - Medtronic generates approximately 7% of its operational revenues from China, and ongoing Sino-U.S. trade tensions could compromise its trade situation [4] - The National Trade Estimate report highlights concerns regarding the impact of Chinese procurement policies on U.S. medical device businesses [3] Dividend and Financials - Medtronic increased its quarterly dividend for the 47th consecutive quarter, but the increase was minimal at just one cent per share, failing to boost the stock price [5] - The current dividend yield is over 3.6%, which outperforms the industry average, with a payout ratio of 53% compared to the industry’s 36.5% [7] Long-Term Prospects - Despite recent challenges, Medtronic is strategically expanding its global presence and gaining market share in various segments, including Cardiovascular and MedSurg [6] - The company is focusing on product launches and regulatory approvals to offset inflation and supply chain disruptions [6] Valuation - Medtronic's stock is trading at a forward 12-month P/E of 13.99X, which is lower than the industry's 19.98X, indicating a cheap valuation [10]

Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Medtronic Plc - Digital Transformation Strategies" company profile has been added to ResearchAndMarkets.com's offering.The report provides comprehensive information and insights into Medtronic's technology activities, focusing on its digital transformation strategies and innovation programs. It offers an overview of Medtronic's technology initiatives, covering partnerships, product launches, and acquisitions. Each technology initiative is detailed with insight ...

Medtronic plc (MDT) recently shared a comprehensive set of new data emphasizing the benefits of the MiniMed 780G insulin pump system. The latest findings demonstrate how the system addresses hyperglycemia and nighttime burden, adding to the pool of evidence proving the system's ability to tackle the difficulties of diabetes, such as managing highs and meal-time management or carb counting while mirroring outcomes across a diverse population.The company presented the series of data at the American Diabetes A ...